Conor’s COSTAR II
This article was originally published in The Gray Sheet
Executive Summary
Firm has completed enrollment of 1,700 patients in its U.S. non-inferiority pivotal study comparing Costar paclitaxel-eluting stent to Boston Scientific's Taxus Express to treat de novo lesions. Conor modified the trial protocol in February due to slower-than-expected enrollment of the multi- versus single-vessel arm (1"The Gray Sheet" Feb. 20, 2006, p. 7). Assuming favorable results, Conor projects FDA approval for the DES in late 2007 or early 2008...
You may also be interested in...
Conor Ramps Up Production Of CoStar Stent To Prep For U.S. Launch
Conor Medsystems is already boosting manufacturing capacity in preparation for the U.S. launch of its CoStar drug-eluting stent, though the product is not slated to hit the market until late next year at the earliest
Conor CoStar Cleared For European Launch; Firm Modifies U.S. Trial Design
Conor Medsystems will launch its CoStar paclitaxel-eluting, cobalt-chromium coronary stent in Europe, having just received a CE mark, the firm said Feb. 17
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”